Panaxia Labs Israel Ltd
TASE:PNAX
Net Margin
Panaxia Labs Israel Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
IL |
P
|
Panaxia Labs Israel Ltd
TASE:PNAX
|
7.9m ILS |
-115%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
722.9B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
360.3B USD |
24%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
206.2B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
185.9B CHF |
24%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
161.1B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
198.9B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
136.3B USD |
13%
|
Panaxia Labs Israel Ltd
Glance View
Panaxia Labs Israel Ltd. engages in the manufacture and distribution of medical cannabis products. The firm provides pharma-grade smokeless cannabis products that provide better delivery systems for patients and physicians when properly assessing safety and dosage. Panaxia pharmaceutical cannabis products are specifically tailored to meet a broad range of needs. It's product portfolio includes: NAXIVA-PANAXOL Advanced kit for preparation of cannabis oil-standardized extract, NAXIVA-PANAXOL Purified extract for inhalation, PANAXIR Medical Cannabis Orodispersible Tablets, PANAXIR SENSE Orange Creamsicle Medical cannabis sublingual drops, PANAXIR CBD Melatonin Tablets, PANAXIR Medical cannabis extracts in ethanol among others.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Panaxia Labs Israel Ltd's most recent financial statements, the company has Net Margin of -115%.